TY -的T1 Mepolizumab有效性和识别super-responders严重哮喘JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02420 -2019欧元六世- 55 - 5 SP - 1902420 AU -哈维,艾琳·s . AU -兰顿,大卫AU - Katelaris,康斯坦斯盟-史蒂文斯,肖恩AU -法拉,克劳德·s . AU -吉尔曼,Andrew AU -哈灵顿,约翰AU -凿,马克AU -科里提科斯,Vicky盟——Radhakrishna Naghmeh盟——Bardin菲利普AU -彼得斯,马修AU -雷诺兹,保罗•n . AU -阿帕姆(John w . AU - Baraket,梅丽莎盟——圆顶礼帽,西蒙AU -鲍登,Jeffrey盟——狗,Jimmy AU - Chung,李平盟——Grainge鳌,Katsoulotos Christopher AU -詹金斯格雷戈里。非盟-李,欢乐盟——麦当劳,凡妮莎·m . AU - Reddel海伦k . AU -轮辋,珍妮特盟-沃克,彼得A.B. AU -吉布森,彼得g . Y1 - 2020/05/01 UR - //www.qdcxjkg.com/content/55/5/1902420.abstract N2 -严重的哮喘是一种高负担疾病。mepolizumab在严重嗜酸性粒细胞性哮喘患者中的实际数据需要用来评估来自随机对照试验的数据是否适用于更广泛的人群。澳大利亚Mepolizumab注册(AMR)旨在评估Mepolizumab治疗澳大利亚严重嗜酸性粒细胞性哮喘的使用、有效性和安全性。重度嗜酸性粒细胞性哮喘患者(n=309)(中位年龄60岁，58%女性)开始使用mepolizumab。他们症状控制较差(哮喘控制问卷(ACQ)-5评分中位数为3.4)，频繁发作(在过去12个月中位数使用口服糖皮质激素(OCS) 3个疗程)，47%需要每日OCS。外周血嗜酸性粒细胞基线中位数为590个细胞·µL−1。合并症常见:变应性鼻炎63%，胃食管反流疾病52%，肥胖46%，鼻息肉34%。与前一年相比，Mepolizumab治疗减少了需要OCS的病情加重(年化率比0.34 (95% CI 0.29-0.41);0.001)和住院(比率0.46(95%可信区间0.33-0.63);术中,0.001)。 Treatment improved symptom control (median ACQ-5 reduced by 2.0 at 6 months), quality of life and lung function. Higher blood eosinophil levels (p=0.003) and later age of asthma onset (p=0.028) predicted a better ACQ-5 response to mepolizumab, whilst being male (p=0.031) or having body mass index ≥30 (p=0.043) predicted a lesser response. Super-responders (upper 25% of ACQ-5 responders, n=61, 24%) had a higher T2 disease burden and fewer comorbidities at baseline.Mepolizumab therapy effectively reduces the significant and long-standing disease burden faced by patients with severe eosinophilic asthma in a real-world setting.In clinical practice, mepolizumab reduces the burden of severe eosinophilic asthma by reducing severe exacerbations and improving asthma control, quality of life and lung function. Super-responders have a T2 phenotype and few comorbidities. http://bit.ly/2UIio4x ER -